Using of non-aspirin non-steroidal anti-inflammatory drugs (NSAIDs) for at least 4 years is associated with an increased risk fatal renal cell carcinoma (RCC), researchers reported at the 2016 Genitourinary Cancers Symposium in San Francisco.
Regular use of non-steroidal anti-inflammatory drugs for 10 years or more increased the risk of dying from renal cell carcinoma nearly 4-fold.
In a pooled multivariate analysis, regular use of aspirin was not significantly associated with RCC risk, but regular use of non-aspirin NSAIDs was associated with a significant 34% increased risk.
Regular aspirin use had no significant effect on the risk of fatal RCC in either women or men.
Aspirin is more of a “natural” drug than the others because it’s an extract of willow tree bark.
Drugs that are concentrated versions of natural substances that have co-evolved with us (like aspirin, opioids, and cannabinoids) seem to be far less damaging, even over the long run, than those we chemically tweak to improve on the naturally-occurring version.
The study found that the risk of fatal RCC increased with increasing duration of non-aspirin NSAID use.
Subjects who regularly used non-aspirin NSAIDs for at least 4 years but less than 10 years and 10 or more years had a nearly 2 times and 4 times increased relative risk of fatal RCC, respectively, compared with those who did not regularly use the drugs.
Women who regularly used non-aspirin NSAIDs for at least 4 years but less than 10 years and 10 or more years had a significant 1.9 times and 4.8-fold times increased relative risk of fatal RCC, respectively.
The researchers found no significant association between regular use of non-aspirin NSAIDs and fatal RCC in men.
This would imply some sort of interaction with the female hormones.